The FDA is up to its old tricks again.
Several recent studies on a popular diabetes drug have linked it to an increased risk of cancer.
Now to most folks, that would be reason enough for a little caution, or at the very least a second look at the med.
Not to the FDA. It seems like it always errs in favor of Big Pharma, rather than the patients who rely on these potentially dangerous meds. Right now, our friends in Washington are telling diabetics to keep on using that potentially dangerous drug while they continue to review these disturbing new studies.
The drug in question is an artificial insulin used by both Type 1 and Type 2 diabetics to control their blood sugar levels. Of four recent studies done on this med and published in June in Diabetologia, three of them found an increased risk of cancer.
At the very least, that should be enough to issue a strong note of caution. But instead of focusing on the three out of four, the ever-optimistic FDA seems to have zeroed in on the one lonely study that didn't show an elevated cancer risk.
What's even more frustrating to me is that the FDA still refuses to acknowledge that many diabetics can bring their condition under control, and others can avoid it altogether, through lifestyle changes, limiting the amounts of these drugs needed in the first place.
It's a stunningly simple approach. A disciplined diet low in carbs and rich in good fats can help diabetics lose weight and lower their cholesterol levels, as well as reduce their risk for heart disease.
Not only that, but they will reduce or even eliminate their need for meds like artificial insulin that not only fail to cure the condition, but also come with the potential for side effects such as an increased risk for cancer.
Someday, I hope our friends at the FDA come around. I hope instead of warning diabetics to stay on their meds, they warn diabetics of the dangers of them, and encourage people to control chronic conditions such as diabetes naturally.
For now, however, the best the FDA will do is tell anyone who gets cancer while on this med – or experiences any other side effects – to report it to their MedWatch Adverse Event Reporting Program.
Don't they realize that by then, it might be too late?